Ikarian Capital, LLC Q3 2023 significant ownership

Add to watchlist

Ikarian Capital, LLC is required to file a 13D/G report to the SEC when the ownership of a company's total stock issue exceeds 5%.

Ikarian Capital, LLC Q3 2023 significant holdings filed using form 13D/G when ownership exceeds 5% of a company's total stock issue.
FiledShares Percentage
Milestone Pharmaceuticals Inc.February 14, 2023460,4161.3%
X4 Pharmaceuticals, IncFebruary 14, 2023349,1330.3%
aTYR PHARMA INCFebruary 14, 202235,0480.1%
Cyclacel Pharmaceuticals, Inc.February 14, 202299,4221.0%
KalVista Pharmaceuticals, Inc.February 14, 202236,5760.2%
Lyra Therapeutics, Inc.February 14, 2022394,5363.0%
Odonate Therapeutics, Inc.February 14, 20221,340,6313.5%
Protara Therapeutics, Inc.February 14, 2022279,2562.5%
Science 37 Holdings, Inc.Sold outFebruary 14, 202200.0%
scPharmaceuticals Inc.February 14, 2022901,3623.3%
Tempest Therapeutics, Inc.February 14, 202258,8030.9%
Celldex Therapeutics, Inc.February 12, 20211,364,9903.5%
Strongbridge Biopharma plcFebruary 12, 20212,440,0283.6%
Verastem, Inc.February 12, 20212,254,5911.3%
YUMANITY THERAPEUTICS, INC.February 12, 2021132,5141.3%
Aerpio Pharmaceuticals, Inc.January 11, 2021475,7781.0%
Lifesci Acquisition II Corp.January 11, 2021512,4506.4%
PROTEOSTASIS THERAPEUTICS, INC.November 18, 20202,650,3475.1%
ArTara Therapeutics, Inc.February 21, 2020307,3085.3%

Compare quarters

Export Ikarian Capital, LLC's holdings

CSVXLS